STOCK TITAN

cbdMD, Inc. - YCBD STOCK NEWS

Welcome to our dedicated page for cbdMD news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on cbdMD stock.

cbdMD, Inc. (NYSE American: YCBD) is a premier provider of high-quality, hemp-derived cannabidiol (CBD) products. Founded in 2015 and headquartered in Charlotte, North Carolina, cbdMD has quickly become one of the most highly trusted and recognized names in the CBD industry. The company offers a broad range of CBD products under its flagship brand cbdMD, as well as its pet-focused brand Paw CBD and its newly launched ATRx Labs line of functional mushroom supplements.

The company's product portfolio includes CBD tinctures, gummies, topicals, capsules, bath bombs, bath salts, sleep aids, and veterinarian-formulated pet CBD products like tinctures, chews, and topicals. It has built a robust distribution network, leveraging its own e-commerce platform, third-party online marketplaces, wholesalers, and a variety of brick-and-mortar retailers across the United States.

In recent developments, cbdMD has introduced innovative products such as the THCV+CBG Energy Softgels, which combine the potency of two dynamic cannabinoids with caffeine and B12 to enhance energy, focus, and clarity. The company's dedication to innovation is also evident in the launch of its CBD+CBG Oil Tincture and the introduction of a new Vice President of Wholesale Sales to expand its market reach.

Financially, cbdMD has been proactive in securing funding to support its growth. Recently, the company entered a securities purchase agreement, raising $1.25 million in gross proceeds to bolster working capital and support the national rollout of its ATRx Labs functional mushroom products. Despite reporting operational losses, cbdMD has implemented cost-cutting measures and strategic initiatives aimed at achieving profitability and enhancing shareholder value.

cbdMD's latest product,

Rhea-AI Summary
cbdMD, Inc. (NYSE American: YCBD) announced the launch of HempMD products and nutraceutical brand ATRx, along with a new functional mushroom product to expand growth opportunities and markets. The company reported a loss from operations of $22.4 million for Fiscal 2023, including one-time intangible impairment charges of $13.2 million. Excluding these charges, significant year-over-year improvements to operating loss were made. The company has made progress on its path to positive cash flow, exhibited operational excellence, and expanded into 160 Sprouts Markets stores across the nation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
-
Rhea-AI Summary
cbdMD, Inc. (NYSE American: YCBD) to Host Conference Call to Discuss Q4 and Full Year Fiscal 2023 Financial Results and Business Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences earnings
-
Rhea-AI Summary
cbdMD (NYSE American: YCBD) wins two bronze awards at the Best in Biz Awards for their CBD Freeze Roll-On and CBD PM Softgel Capsules - NSF Certified for Sport. The Freeze Roll-On provides quick relief from temporary muscle and joint discomfort, while the Softgel Capsules are the first CBD product to earn the NSF Certified for Sport certification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
Rhea-AI Summary
cbdMD cancels vote on automatic conversion of Series A Preferred Stock due to insufficient proxies. Management to focus on business and explore strategic alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
none
-
Rhea-AI Summary
cbdMD announces partnership with Club Sport Herediano, becoming the official sponsor of the FIFA-affiliated professional Costa Rican soccer team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
partnership
-
Rhea-AI Summary
cbdMD, Inc. adjourns Special Meeting of Shareholders to October 26, 2023 to solicit additional proxies for proposal to approve amendment to Certificate of Designation for Series A Preferred Stock. Board of Directors believes approval of proposal is in best interests of cbdMD and its shareholders. Shareholders encouraged to vote as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
Rhea-AI Summary
cbdMD publishes safety data supporting safe upper dose of proprietary Broad Spectrum CBD blend
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
none
-
Rhea-AI Summary
cbdMD reminds shareholders to vote ahead of the special meeting on September 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.5%
Tags
none
-
Rhea-AI Summary
cbdMD's Paw CBD brand receives 'Dog Hip & Joint Product of the Year' award for their Hip+Joint Soft Chews, enhancing overall wellbeing and supporting mobility in dogs. The chews are certified by NASC and come in three strengths. The award highlights cbdMD's commitment to innovative CBD products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
Rhea-AI Summary
cbdMD, Inc. suspends monthly cash dividend on Series A Preferred Stock to conserve cash for sales increase, product development, research, and profitability. Dividends will accumulate until sufficient working capital is restored. Suspension may impact capital raising. Shareholders to vote on automatic conversion of Series A Preferred to common stock on September 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends

FAQ

What is the current stock price of cbdMD (YCBD)?

The current stock price of cbdMD (YCBD) is $0.36 as of December 20, 2024.

What is the market cap of cbdMD (YCBD)?

The market cap of cbdMD (YCBD) is approximately 1.7M.

What does cbdMD, Inc. specialize in?

cbdMD, Inc. specializes in producing and distributing high-quality hemp-derived cannabidiol (CBD) products, including tinctures, gummies, topicals, capsules, and pet products.

What are cbdMD's latest product innovations?

cbdMD has recently introduced THCV+CBG Energy Softgels, CBD+CBG Oil Tincture, and Max Chill Dragon Fruit D9 Gummies, as well as launching the ATRx Labs line of functional mushroom supplements.

How does cbdMD distribute its products?

cbdMD distributes its products through its e-commerce website, third-party online marketplaces, wholesalers, and various brick-and-mortar retailers in the United States.

What recent financial steps has cbdMD taken?

cbdMD recently entered a securities purchase agreement to raise $1.25 million in gross proceeds to support working capital and the national rollout of its ATRx Labs products.

What is the significance of cbdMD's ATRx Labs line?

The ATRx Labs line focuses on functional mushroom supplements designed to support various health needs. It marks cbdMD's expansion into non-CBD health products.

Is cbdMD financially stable?

While cbdMD has reported operational losses, it has implemented significant cost-cutting measures and strategic initiatives aimed at achieving profitability and enhancing shareholder value.

What challenges is cbdMD currently facing?

cbdMD received a notice from the NYSE American regarding non-compliance with certain listing standards. The company is working on a compliance plan to address this issue.

Where is cbdMD headquartered?

cbdMD is headquartered in Charlotte, North Carolina.

Who recently joined the cbdMD team?

Joe Baghadjian recently joined cbdMD as Vice President of Wholesale Sales, bringing extensive experience in CBD sales and a scientific background.

What are cbdMD's future plans?

cbdMD plans to focus on achieving positive net income, expanding its product offerings, and enhancing its market presence through strategic initiatives and cost-cutting measures.

cbdMD, Inc.

NYSE:YCBD

YCBD Rankings

YCBD Stock Data

1.65M
3.84M
16.11%
3.33%
5.47%
Drug Manufacturers - Specialty & Generic
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States of America
CHARLOTTE